An early-stage venture capital investor is focused on globally scalable technology companies with connections to Southeast Asia and the United States. The firm primarily invests at the Pre-Seed, Seed, and Pre-Series A stages, typically deploying approximately $150K–$1M per company and generally targeting ownership positions of 5–15%. A meaningful portion of the firm’s capital is allocated to life sciences and healthcare innovation. The firm leverages technical expertise, entrepreneurial experience, and international operating networks to support early-stage companies pursuing global growth. 

Within life sciences and healthcare, the firm focuses on techbio and technology-enabled healthcare innovation. Areas of interest include computational biology, artificial intelligence and machine learning, protein and RNA technologies, gene editing and CRISPR, precision therapeutics, AI-enabled drug discovery, biomaterials, regenerative medicine, tissue engineering, synthetic biology, screening and diagnostics, digital health, healthcare analytics, and health data infrastructure. The firm is comfortable investing at very early stages, including preclinical and research-stage opportunities, and is generally indication-agnostic, with additional interest in neurotechnology and neuroscience. 

From a company and management team perspective, the firm seeks ambitious founders and technically strong teams developing differentiated intellectual property and defensible technology platforms. The firm can lead or co-invest and generally seeks board participation when leading a financing. The firm actively supports portfolio companies with technology strategy, business scaling, international expansion, recruiting, and future fundraising through its network of operators, technologists, and industry experts. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a U.S.-based healthcare investment manager focused exclusively on biotechnology and biopharmaceutical companies. The firm invests across both public and private markets and has more than two decades of experience investing in life sciences. Through its dedicated private investment strategy, the firm supports emerging biotechnology companies from Seed through Series B, with initial investments typically averaging approximately $10M and significant capacity for follow-on participation. Investments are primarily structured as equity, although convertible instruments may be considered for select Seed-stage opportunities. The firm primarily targets companies in the United States and Europe. 

The firm invests exclusively in therapeutics and is broadly agnostic across modalities and disease areas. The firm evaluates small molecules, biologics, antibodies, RNA therapeutics, cell and gene therapies, and other emerging therapeutic platforms. Areas of interest include oncology, immunology, rare diseases, metabolic disorders, and other indications characterized by significant unmet medical need. The firm is comfortable investing from the preclinical stage onward and prioritizes differentiated science, strong biological rationale, and programs capable of generating meaningful clinical value. 

From a company and management team perspective, the firm seeks strong scientific founders and experienced leadership teams capable of advancing complex therapeutic programs through key clinical and value-inflection milestones. The firm can lead, co-lead, or participate in investment syndicates and may seek board representation or observer rights. The firm takes an active approach to portfolio support, working with management on financing strategy, clinical development, business development, and long-term company building. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is the corporate venture capital arm of a diversified global company with substantial healthcare operations. The firm operates through an evergreen investment model and invests globally, with particular activity across North America, Europe, and Asia. Initial investments typically range from approximately $1M–$3M, with the capacity to invest $5M or more over the life of a portfolio company. The firm pursues strategic investments that complement its parent organization’s healthcare businesses and long-term innovation priorities. 

The firm invests across pharmaceuticals, medical devices, diagnostics, digital health, bioprocessing, and other enabling healthcare technologies. Areas of particular interest include pain management, critical care, kidney disease, musculoskeletal disorders, drug delivery, patient monitoring, digital therapeutics, and technologies that improve healthcare delivery and clinical outcomes. The firm is generally stage-agnostic but tends to favor opportunities demonstrating meaningful technical validation, preclinical proof-of-concept, or early clinical data. The firm evaluates investments partly based on their potential strategic relevance to its broader healthcare capabilities. 

From a company and management team perspective, the firm invests exclusively in private companies and is comfortable partnering with early-stage teams that are still developing their leadership and operational capabilities. The firm takes a collaborative, strategic approach and can provide access to global healthcare expertise, technical and manufacturing resources, and commercial relationships. The firm generally seeks board participation or observer rights and actively supports portfolio companies with business development, strategic partnerships, product development, and long-term growth. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a venture capital investor with a global investment mandate and a significant allocation to healthcare and life sciences. The firm typically invests approximately $2.5M per company and participates in Seed through Series B financings. The firm can act as either a lead investor or co-investor and invests globally, with particular interest in opportunities across the United States, China, and Europe. The firm seeks companies with strong and defensible intellectual property that can provide meaningful downside protection and competitive differentiation. 

The firm invests across therapeutics, medical devices, diagnostics, and healthcare IT and is broadly agnostic across indications. The firm has particular interest in medical devices and cardiovascular technologies and considers devices across regulatory pathways and stages of development. Within therapeutics, the firm evaluates programs ranging from preclinical development through Phase III, while medical device and diagnostic opportunities may be considered at any development stage. The firm also evaluates healthcare technologies incorporating automation and robotics where relevant. 

From a company and management team perspective, the firm invests exclusively in privately held companies and does not impose specific management team requirements. The firm places significant emphasis on differentiated technology and strong intellectual property. The firm may seek a board seat in select circumstances but generally prefers board observer rights, allowing the firm to remain actively engaged while supporting portfolio companies alongside other investors. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.